SCHEMBL854534

SCHEMBL854534

Cc1ccc(-c2ncsc2SCC(=O)Nc2ccc(-c3ccc(CC(=O)O)cc3)cc2)c(Cl)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DGAT1 O75907 2/20 0.42
KDM4E B2RXH2 4/20 0.41
NPC1 O15118 3/20 0.41
RAB9A P51151 3/20 0.41
KMT2A Q03164 6/20 0.40
MEN1 O00255 5/20 0.40
SMN1; SMN2 Q16637 5/20 0.40
MAPT P10636 5/20 0.40
ALDH1A1 P00352 4/20 0.40
POLB P06746 2/20 0.40
HPGD P15428 1/20 0.40
WNT3A P56704 1/20 0.39
PTGDR2 Q9Y5Y4 1/20 0.38
HSP90AA1 P07900 1/20 0.38
SOAT1 P35610 1/20 0.38
LMNA P02545 1/20 0.38
TP53 P04637 2/20 0.38
HPSE Q9Y251 1/20 0.38
FFAR1 O14842 1/20 0.37
GLA P06280 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9911393 0.91 DGAT1 (0.44) DGAT1KDM4EKMT2AMEN1MAPT
SCHEMBL861156 0.86 KMT2A (0.43) DGAT1KDM4ENPC1RAB9AKMT2A
SCHEMBL845612 0.81 GRK6 (0.40) KDM4EKMT2AMEN1ALDH1A1HPGD
SCHEMBL861073 0.77 SMN1; SMN2 (0.41) DGAT1KDM4ENPC1RAB9AKMT2A
SCHEMBL846103 0.76 MAPT (0.46) KDM4ENPC1RAB9AKMT2AMEN1
SCHEMBL861726 0.69 POLB (0.41) DGAT1NPC1RAB9AKMT2AMEN1
SCHEMBL9612026 0.68 LMNA (0.41) KMT2AMEN1SMN1; SMN2MAPTALDH1A1
SCHEMBL861475 0.64 POLB (0.44) SMN1; SMN2MAPTALDH1A1POLBLMNA
SCHEMBL9610108 0.64 MEN1 (0.48) KDM4ENPC1KMT2AMEN1SMN1; SMN2
SCHEMBL11845509 0.63 HTT (0.70) KDM4ENPC1RAB9AKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8372807-B2 Methods of modulating uric acid levels ARDEA BIOSCIENCES, INC. (US) 2013-02-12 US disclosed
US-8372807-B2 Methods of modulating uric acid levels ARDEA BIOSCIENCES, INC. (US) 2013-02-12 US disclosed
US-20120135929-A1 Methods Of Modulating Uric Acid Levels ARDEA BIOSCIENCES INC. (US) 2012-05-31 US disclosed
US-20120135929-A1 Methods Of Modulating Uric Acid Levels ARDEA BIOSCIENCES INC. (US) 2012-05-31 US disclosed
EP-2432468-A2 METHODS OF MODULATING URIC ACID LEVELS Ardea Biosciences, Inc. (US) 2012-03-28 EP disclosed
WO-2010135536-A2 METHODS OF MODULATING URIC ACID LEVELS ARDEA BIOSCIENCES, INC. (US) 2010-11-25 WO disclosed
WO-2010135536-A2 METHODS OF MODULATING URIC ACID LEVELS ARDEA BIOSCIENCES, INC. (US) 2010-11-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120135929-A1 Methods Of Modulating Uric Acid Levels XDH, PON1, OAT DGAT1 1133/4885KDM4E 3253/4885NPC1 889/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.